Viking Therapeutics Stock News

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

The FTC's attempt to block the merger between Amgen and Horizon Therapeutics is weighing on small- and mid-cap biotech stocks. Shares of Viking Therapeutics are sinking in lockstep with its broader pe

A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.

Viking's long-awaited midstage NASH trial results were announced today, and they didn't disappoint. Investors bid up the biotech's shares in response to this positive clinical update, despite a dour d

Viking unveiled promising test results Tuesday for a liver disease drug, but VKTX stock reversed its premarket gain and sank at the open. The post Top 1% Biotech Viking Therapeutics Backs Off Its Reco

Viking Therapeutics Inc (NASDAQ:VKTX) today announced a win for its experimental drug to treat patients with a type of fatty liver disease called non-alcoholic steatohepatitis (NASH).

Viking Therapeutics unveiled promising test results Tuesday for a liver disease treatment, sending top-rated VKTX stock to a record high. The post Why Top 1% Biotech Viking Therapeutics Is At The Brin

Viking Therapeutics' sizzling upswing took a slight breather this morning. However, most shareholders appear to have held on through today's volatility.

Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics were among the most volatile in t

H.C. Wainwright raised its price target on the biotech stock from $21 to $33 a share. Bullish investors on the stock seemingly took this as a strong buy signal.

Viking Therapeutics, Inc. (VKTX) Q1 2023 - Earnings Call Transcript.

TG Therapeutics' MS drug Briumvi has had strong early sales. Viking Therapeutics reports solid clinical results from its obesity drug VK2735.

The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatment VK2735 caused its shares to rally more

Following positive data for its obesity drug (VK2735), Viking Therapeutics shares rallied aggressively. In Q2, Viking is poised to release its Phase 2b (VOYAGE) trial data of VK2809 for non-alcoholic

Several key themes are emerging in the stock investing landscape. These five stocks are poised to benefit from these powerful trends.